(Q57424151)

English

Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer

scientific article published on 25 August 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

0 references

Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategies (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

cancer research

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

Fotios Loupakis

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Marta Schirripa

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Diana Giannarelli

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Vittorina Zagonel

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Giampaolo Tortora

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Alfredo Falcone

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

author name string

Chiara Cremolini

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Vanja Vaccaro

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Federica Cuppone

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Francesco Cognetti

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

language of work or name

0 references

publication date

25 August 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

118

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1523-1532

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Biomarkers to predict the clinical efficacy of bevacizumab in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

EGFR antibodies in colorectal cancer: where do they belong?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Meta-analyses of randomised clinical trials in oncology.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Practical methods for incorporating summary time-to-event data into meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Interpreting Measures of Treatment Effect in Cancer Clinical Trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Confidence intervals for the number needed to treat

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

What kind of evidence do patients and practitioners need: evidence profiles based on 5 key evidence-based principles to summarize data on benefits and harms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Evidence profiles for breast cancer: benefit/harms data based on the totality of randomized evidence

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Biomarkers and surrogate end points--the challenge of statistical validation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

21 January 2018

Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

7 January 2021

based on heuristic

inferred from DOI database lookup

Introduction to Meta-Analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26460

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.26460

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22009364%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57424151&oldid=2170854706"